期刊文献+

ERβ、C-erbB-2及bcl-2蛋白在乳腺癌组织的表达及意义 被引量:2

The expression and significance of ERβ,C-erbB-2 and bcl-2 protein in breast cancer
下载PDF
导出
摘要 目的:检测乳腺癌组织中雌激素受体β(ERβ)、C-erbB-2和bcl-2蛋白的表达情况,并分析ERβ蛋白的表达与组织学分级、C-erbB-2及bcl-2蛋白表达的关系。方法:采用免疫组化S-P法检测96例乳腺癌组织标本中ERβ、C-erbB-2及bcl-2蛋白的表达情况,并作统计学分析。结果:96例乳腺癌组织标本中,ERβ、C-erbB-2及bcl-2蛋白阳性表达率分别为64.6%、36.5%和51.0%;ERβ蛋白的表达与组织学分级、C-erbB-2蛋白的表达呈负相关(P<0.05),与bcl-2蛋白的表达呈正相关,与腋淋巴结状态无关(P>0.05)。结论:ERβ蛋白表达可能是乳腺癌患者预后良好的指标。 Objectlve:To detect the expressions of ERβ, C -erbB -2 and bel -2 protein in breast cancer , and analyze the relationship between the expression of ERβ protein and tumor grade, the expression of C - erbB - 2 and bel - 2 protein. Methods: Immunohistochemistry S - P method was used to detect the expression of ERβ, C - erbB - 2 and bcl - 2 protein in 96 breast cancer samples. Rssult of detection were analyzed statistically. Results: The positive expression rates of ERβ, C - efbB -2 and bcl -2 protein were 64.6%, 36.5% and 51.0% respectively;The expression of ERβ protein had a negtive correlation with tumor grade and the expression of C - erbB - 2 protein(P 〈 0.05 ), and had a positive correlation with the expression of bcl -2 protein, no correlation with axillary lymph node status(P 〉 0.05 ). Conclusion: ERβ protein may be a useful marker which predicts good prognosis of breast cancer patients.
出处 《现代肿瘤医学》 CAS 2008年第1期38-40,共3页 Journal of Modern Oncology
基金 安徽省卫生厅科研基金资助项目(2002A038)
关键词 乳腺癌 雌激素受体Β 预后 breast cancer estrogen receptor beta prognosis
  • 相关文献

参考文献13

  • 1姚永忠,王雪晨,张丽华.乳腺癌c-erbB-2、PCNA的表达及其与ER、PR的相关性研究[J].实用医学杂志,2005,21(2):136-138. 被引量:10
  • 2徐胜前,张春辉,尤其俋.乳腺癌雌孕激素受体与C-erbB-2基因蛋白表达及相关分析研究[J].南通大学学报(医学版),2005,25(3):180-182. 被引量:2
  • 3汪子书,秦凤展,吴穷,佘明金.女性乳腺癌组织ERα、ERβ的表达及其意义[J].蚌埠医学院学报,2004,29(6):482-485. 被引量:2
  • 4Dotzlaw H, Leygue E, Watson PH, et al. Expression of estrogen receptor - beta in human breast tumors [ J ]. J Clin Endocrinol Metab, 1997,82(7 ) :2371 - 2374.
  • 5Paech K, Webb P, Kuiper GG, et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites [ J ]. Science, 1997,277 (5331 ) : 1508 - 1510.
  • 6Yang Q, Sakurai T, Yoshimura G, et al. Prognostic value of Bcl - 2 in invasive breast cancer receiving chemotherapy and endocrine therapy [ J ]. Oncol Rep, 2003,10 ( 1 ) : 121 - 125.
  • 7Arteaga CL, Moulder SL, Yakes FM. HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer[ J ]. Semin Oncol, 2002,29 ( 3 Suppl 11 ) :4 - 10.
  • 8Konecny G, Untch M, Arboleda J, et al. Her - 2/neu and urokinase - type plasminogen activator and its inhibitor in breast cancer [J]. Clin Cancer Res, 2001,7(8) :2448 -2457.
  • 9Nunes RA, Harris LN. The HER2 extracellular domain as a prognostic and predictive factor in breast cancer[J]. Clin Breast Cancer, 2002, 3(2) :125 - 137.
  • 10Moreno A, Figueras A, Lloveras B, et al. Apoptosis in ductal carcinoma in situ of the breast[J]. Breast J, 2001,7(4) :245-248.

二级参考文献32

  • 1胡勇,饶慧蓉,吴强.癌基因c─erbB─2、抗癌基因p53在乳腺癌中表达的临床病理研究[J].临床与实验病理学杂志,1995,11(1):6-10. 被引量:41
  • 2Wright C, Angus B, Nicholsons S, et al. Expression of c-erbB-2 oncoprotein: A prognostic indicator in human breast cancer. Cancer Res, 1989, 49(8): 2087-2090.
  • 3Roetger A, Merschjann A, Dittmar T, et al. Selection of potentionally metastatic subpopulations expressing c-erbB-2 from breast cancer tissue by use of an extrevasation model. Am J Pathol, 1998, 153(6):1797 - 1806.
  • 4Sauer T, Beraki K, Jebsen PW, et al. Numerical aberrations of chromosome 17 inter,phase cell nuclei of breast cancinoma cell: lack of correlation with abnormal expression of p53, neu and nm23 protein.APMIS, 1998, 106(10): 921-927.
  • 5Mittra I, Radkar AA, Badwe B.A. Prognosis of breast cancer evidence for interaction between c-erbB-2 overpression and number of involved axillary lymph nodes. J Surg Oncol, 1995, 60(2): 106 - 111.
  • 6McGuire WL, Clack GM. Prognostic factor and treatment decisions in axillary-node-negative breast cancer. N Engl J Med, 1992, 326(26):1756 - 1759.
  • 7Dowsett M, Harper-Wynne C, Boeddinghaus I, et al. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res, 2001,61 (23): 8452 - 8458.
  • 8Nomura Y, Miura S, Koyama H, et al. Relative effect of steroid hormone receptors on the prognosis of patients with operable breast cancer. Cancer, 1992,69(1): 153 - 164.
  • 9Kato T, Kimura T, Takami N, et al. New prognostic factors associated with long-term survival in node-negative breast cancer patients. Breast Cancer, 1999, 6(4): 370-377.
  • 10Jeziorski A, Blonski JZ, Niewiadomska H. The expression of products of oncogens c-erbB-2 and EGFR and proliferating antigens Ki67 and PCNA in primary invasive ductal cancer of female breast. J Exp Clin Cancer Res, 2000, 19(1): 61 -67.

共引文献11

同被引文献12

引证文献2

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部